Former Pfizer chief scientist joins Immunai’s board of directors
Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.
Dr. Noam Solomon, CEO of Immunai(photo credit: Courtesy of Immunai)ByMAARIV ONLINE